Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.

ABSTRACT:

SUBMITTER: Chuang JC 

PROVIDER: S-EPMC4630528 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature